BOC2抑制N-甲酰肽/甲酰肽受体信号通路减轻SAP炎症损伤的机制研究

doi:10.11958/20240774

天津医药 ›› 2024, Vol. 52 ›› Issue (10): 1031-1037.doi: 10.11958/20240774

BOC2抑制N-甲酰肽/甲酰肽受体信号通路减轻SAP炎症损伤的机制研究

张桂贤¹(), 刘大卫¹, 李文畅¹, 蔡隽¹, 宗文辉¹, 刘洪斌², 赵秀梅¹^,^△()

1 天津市医药科学研究所（邮编300020）
2 天津市和平区卫生健康委员会

收稿日期:2024-06-14 修回日期:2024-08-27 出版日期:2024-10-15 发布日期:2024-10-14
通讯作者: △ E-mail：zxmmlg@163.com
作者简介:张桂贤（1981），女，副研究员，主要从事急、慢性胰腺炎药理学方面研究。E-mail：zhangguixian2007@aliyun.com
基金资助:
国家自然科学基金资助项目(82304797);天津市科学技术局重点项目(21JCZDJC01220);天津市科学技术局面上项目(21JCYBJC01680);天津市科学技术局青年项目(23JCQNJC00600);天津市卫生健康科技项目(TJWJ2022MS049);天津市卫生健康科技项目(TJWJ2024MS047)

Mechanism study of BOC2 alleviating SAP inflammatory damage by inhibiting N-formyl peptide/formyl peptide receptor pathway

ZHANG Guixian¹(), LIU Dawei¹, LI Wenchang¹, CAI Jun¹, ZONG Wenhui¹, LIU Hongbin², ZHAO Xiumei¹^,^△()

1 Tianjin Institute of Medical & Pharmaceutical Sciences, Tianjin 300020, China
2 Health Commission of Heping District, Tianjin

Received:2024-06-14 Revised:2024-08-27 Published:2024-10-15 Online:2024-10-14
Contact: △ E-mail：zxmmlg@163.com

张桂贤, 刘大卫, 李文畅, 蔡隽, 宗文辉, 刘洪斌, 赵秀梅. BOC2抑制N-甲酰肽/甲酰肽受体信号通路减轻SAP炎症损伤的机制研究[J]. 天津医药, 2024, 52(10): 1031-1037.

ZHANG Guixian, LIU Dawei, LI Wenchang, CAI Jun, ZONG Wenhui, LIU Hongbin, ZHAO Xiumei. Mechanism study of BOC2 alleviating SAP inflammatory damage by inhibiting N-formyl peptide/formyl peptide receptor pathway[J]. Tianjin Medical Journal, 2024, 52(10): 1031-1037.

摘要/Abstract

摘要：

目的观察BOC-Phe-Leu-Phe-Leu-Phe（BOC2）对重症急性胰腺炎（SAP）大鼠血中6种线粒体N-甲酰肽（NFPs）及胰腺组织中2种甲酰肽受体（FPRs）表达的影响，探讨其减轻SAP炎症损伤的机制。方法将40只雄性SD大鼠随机分为4组：假手术组，模型组，BOC2低、高剂量组（分别为0.1、0.2 mg/kg），每组10只。后3组以胆胰管逆行注射5%牛磺胆酸钠（50 mg/kg）制备SAP模型。造模结束后0.5 h腹腔注射相应剂量药物，4 h取材。苏木精-伊红染色观察胰腺病理改变；蛋白免疫印迹法检测血浆中NFPs的表达；免疫组化法检测胰腺FPRs表达；酶联免疫吸附试验检测血浆中白细胞介素（IL）-1β、IL-6和肿瘤坏死因子（TNF）-α水平；实时荧光定量聚合酶链反应检测胰腺局部组织炎性因子的表达。结果与模型组比较，BOC2低、高剂量组胰腺出血、腺泡细胞坏死、炎性细胞浸润、水肿等病理现象均改善；胰腺病理评分，血浆线粒体NADH-泛素氧化还原酶链（MT-ND）1、MT-ND2、MT-ND3、MT-ND5、MT-ND6表达，胰腺FPRs表达，血浆及胰腺组织中3种炎性因子表达均下降（P<0.05）。结论 BOC2可通过拮抗线粒体NFPs/FPRs信号通路减少炎性因子产生，减轻SAP炎症损伤。

关键词: 胰腺炎, N-甲酰甲硫氨酰亮氨酰-苯丙氨酸, 受体, 甲酰肽, 线粒体, BOC2, 重症急性胰腺炎

Abstract:

Objective To observe the effect of BOC-Phe-Leu-Phe-Leu-Phe (BOC2) on the expression of six types of mitochondrial N-formyl peptides (NFPs) in blood and two formyl peptide receptors (FPRs) in pancreatic tissue of rats with severe acute pancreatitis (SAP), and to explore its mechanism of alleviating inflammatory damage of SAP. Methods Forty male SD rats were randomly divided into four groups: the sham group, the SAP model group, the BOC2 low-dose and the BOC2 high-dose group (0.1 and 0.2 mg/kg), with 10 animals in each group. The SAP model was prepared by retrograde injection of 5% sodium taurocholate (50 mg/kg) into biliary and pancreatic ducts in the last 3 groups. BOC2 was intraperitoneally injected at 0.5 hours after SAP modeling, and samples were taken 4 hours after modeling. HE staining was used to observe pathological changes in pancreas. Western blot assay was used to detect the expression of NFPs in plasma. IHC staining was used to detect the expression of FPRs in pancreatic tissue. ELISA was used to detect interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α levels in plasma. qPCR was used to detect expression levels of inflammatory factors in local pancreatic tissue. Results Compared with the model group, the BOC2 high-dose group and the BOC2 low- dose group showed improvement in pathological phenomena, such as pancreatic bleeding, acinar cell necrosis, inflammatory cell infiltration and edema. The pancreatic injury score, pancreatic FPRs expression, plasma MT-ND1, MT-ND2, MT-ND3, MT-ND5, MT-ND6 expression, as well as expression levels of three inflammatory factors in plasma and local pancreatic tissue, were significantly reduced (P<0.05). Conclusion BOC2 can reduce the production of inflammatory factors and alleviate SAP inflammatory damage by antagonizing mitochondrial NFPs/FPRs signaling pathway.

Key words: pancreatitis, N-formylmethionine leucyl-phenylalanine, receptors, formyl peptide, mitochondria, BOC2, severe acute pancreatitis

中图分类号:

R576.1

图/表 10

参考文献 22

[1]	中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 浙江实用医学, 2021, 26(6):511-519,535.
	Chinese Pancreatic Surgery Association,Chinese Society of Surgery,Chinese Medical Association. Guidelines for diagnosis and treatment of acute pancreatitis in China (2021)[J]. Zhejiang Practical Medicine, 2021, 26(6):511-519,535. doi:10.16794/j.cnki.cn33-1207/r.2021.06.003.
[2]	张雪奇, 兑秋李, 张云娜, 等. 急性胰腺炎的中医药治疗知识图谱可视化分析[J]. 中国中西医结合外科杂志, 2023, 29(6):746-752.
	ZHANG X Q, DUI Q L, ZHANG Y N, et al. Visual analysis of knowledge graph of traditional Chinese medicine treatment of acute pancreatitis[J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine, 2023, 29(6):746-752. doi:10.3969/j.issn.1007-6948.2023.05.005.
[3]	ZEREM E, KURTCEHAJIC A, KUNOSIĆ S, et al. Current trends in acute pancreatitis:diagnostic and therapeutic challenges[J]. World J Gastroenterol, 2023, 29(18):2747-2763. doi:10.3748/wjg.v29.i18.2747.
[4]	LU Y Y, LI B Q, WEI M, et al. HDL inhibits pancreatic acinar cell NLRP3 inflammasome activation and protect against acinar cell pyroptosis in acute pancreatitis[J]. Int Immunopharmacol, 2023, 125(Pt A):110950. doi:10.1016/j.intimp.2023.110950.
[5]	BARRERA GUTIERREZ J C, GREENBURG I, SHAH J, et al. Severe acute pancreatitis prediction:a model derived from a prospective registry cohort[J]. Cureus, 2023, 15(10):e46809. doi:10.7759/cureus.46809.
[6]	LIU Y, CUI H, MEI C, et al. Sirtuin4 alleviates severe acute pancreatitis by regulating HIF-1α/HO-1 mediated ferroptosis[J]. Cell Death Dis, 2023, 14(10):694. doi:10.1038/s41419-023-06216-x.
[7]	LI L, ZHANG Q, FENG Y, et al. A novel serum exosomal miRNA signature in the early prediction of persistent organ failure in patients with acute pancreatitis[J]. Ann Surg, 2024 Feb 7. doi: 10.1097/SLA.0000000000006229. Online ahead of print.
[8]	CHEN G, WANG X, LIAO Q, et al. Structural basis for recognition of N-formyl peptides as pathogen-associated molecular patterns[J]. Nat Commun, 2022, 13(1):5232. doi:10.1038/s41467-022-32822-y.
[9]	D'AMICO R, FUSCO R, CORDARO M, et al. Modulation of NLRP3 inflammasome through formyl peptide receptor 1 (FPR-1) pathway as a new therapeutic target in bronchiolitis obliterans syndrome[J]. Int J Mol Sci, 2020, 21(6):2144. doi:10.3390/ijms21062144.
[10]	CHEN T, XIONG M, ZONG X, et al. Structural basis of ligand binding modes at the human formyl peptide receptor 2[J]. Nat Commun, 2020, 11(1):1208. doi:10.1038/s41467-020-15009-1.
[11]	TSAI Y F, YANG S C, CHANG W Y, et al. Garcinia multiflora inhibits FPR1-mediated neutrophil activation and protects against acute lung injury[J]. Cell Physiol Biochem, 2018, 51(6):2776-2793. doi:10.1159/000495970.
[12]	肖懿, 张桂贤, 高瑞芳, 等. 重症急性胰腺炎大鼠血浆中6种线粒体N-甲酰肽及胰腺FPR1的表达研究[J]. 天津医药, 2022, 50(2):150-154.
	XIAO Y, ZHANG G X, GAO R F, et al. The expression of six kinds of mitochondrial N-formyl peptides in plasma and pancreatic FPR1 in severe acute pancreatitis rats[J]. Tianjin Med J, 2022, 50(2):150-154. doi:10.11958/20211715.
[13]	胡泉东, 杨玉娟, 余珊珊. 脂氧素受体激动剂BML-111对大鼠急性肝损伤的干预作用及其机制[J]. 中国应用生理学杂志, 2020, 36(5):494-498,532.
	HU Q D, YANG Y J, YU S S. Intervention effect of lipoxygen receptor agonist BML-111 on acute liver injury in rats and its mechanism[J]. Chin J Appl Physiol, 2020, 36(5):494-498,532. doi:10.12047/j.cjap.5990.2020.105.
[14]	肖懿, 冯志乔, 张桂贤, 等. 血必净注射液调节线粒体N-甲酰肽/NLRP3炎症通路对重症急性胰腺炎大鼠模型的治疗机制[J]. 中国实验方剂学杂志, 2022, 28(7):88-94.
	XIAO Y, FENG Z Q, ZHANG G X, et al. Xuebijing injection regulates mitochondrial N-formyl peptides/NLRP3 inflammatory pathway to treat severe acute pancreatitis in rats[J]. Chin J Exp Tradit Med Form, 2022, 28(7):88-94. doi:10.13422/j.cnki.syfjx.20220738.
[15]	ITAGAKI K, KACZMAREK E, KWON W Y, et al. Formyl peptide receptor-1 blockade prevents receptor regulation by mitochondrial danger-associated molecular patterns and preserves neutrophil function after trauma[J]. Crit Care Med, 2020, 48(2):e123-e132. doi:10.1097/CCM.0000000000004094.
[16]	WINTHER M, DAHLGREN C, FORSMAN H. Formyl peptide receptors in mice and men:similarities and differences in recognition of conventional ligands and modulating lipopeptides[J]. Basic Clin Pharmacol Toxicol, 2018, 122(2):191-198. doi:10.1111/bcpt.12903.
[17]	ABOUELASRAR SALAMA S, GOUWY M, VAN DAMME J, et al. Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands[J]. Front Endocrinol (Lausanne), 2023, 14:1119227. doi:10.3389/fendo.2023.1119227.
[18]	QIN C X, NORLING L V, VECCHIO E A, et al. Formylpeptide receptor 2:nomenclature,structure,signalling and translational perspectives:IUPHAR review 35[J]. Br J Pharmacol, 2022, 179(19):4617-4639. doi:10.1111/bph.15919.
[19]	WEN X, XU X, SUN W, et al. G-protein-coupled formyl peptide receptors play a dual role in neutrophil chemotaxis and bacterial phagocytosis[J]. Mol Biol Cell, 2019, 30(3):346-356. doi:10.1091/mbc.E18-06-0358.
[20]	CAO Y, LI F, SUN Z, et al. Regulation of microtubule stability in pulmonary microvascular endothelial cells in rats with severe acute pancreatitis:Qingyi decoction is a potential CDK5 inhibitor[J]. J Inflamm Res, 2024, 17:2513-2530. doi:10.2147/JIR.S451755.
[21]	FAN J H, LUO N, LIU G F, et al. Mechanism of annexin A1/N-formylpeptide receptor regulation of macrophage function to inhibit hepatic stellate cell activation through Wnt/β-catenin pathway[J]. World J Gastroenterol, 2023, 29(22):3422-3439. doi:10.3748/wjg.v29.i22.3422.
[22]	FORSMAN H, WU Y L, MÅRTENSSON J, et al. AZ2158 is a more potent formyl peptide receptor 1 inhibitor than the commonly used peptide antagonists in abolishing neutrophil chemotaxis[J]. Biochem Pharmacol, 2023, 211:115529. doi:10.1016/j.bcp.2023.115529.

基因	引物序列（5′→3′）	产物大小/bp
IL-1β	上游：GCAGCTTTCGACAGTGAGGA	98
	下游：TCTGGACAGCCCAAGTCAAG	98
IL-6	上游：CACTTCACAAGTCGGAGGCT	114
	下游：TCTGACAGTGCATCATCGCT	114
TNF-α	上游：CTCGAGTGACAAGCCCGTAG	187
	下游：GCAGCCTTGTCCCTTGAAGA	187
GAPDH	上游：GACATGCCGCCTGGAGAAAC	92
	下游：AGCCCAGGATGCCCTTTAGT	92

基因	引物序列（5′→3′）	产物大小/bp
IL-1β	上游：GCAGCTTTCGACAGTGAGGA	98
	下游：TCTGGACAGCCCAAGTCAAG	98
IL-6	上游：CACTTCACAAGTCGGAGGCT	114
	下游：TCTGACAGTGCATCATCGCT	114
TNF-α	上游：CTCGAGTGACAAGCCCGTAG	187
	下游：GCAGCCTTGTCCCTTGAAGA	187
GAPDH	上游：GACATGCCGCCTGGAGAAAC	92
	下游：AGCCCAGGATGCCCTTTAGT	92

组别	腹水量/mL	胰腺干湿质量比/（g/g）
假手术组	0	0.51±0.09
模型组	7.89±0.53^a	0.22±0.05^a
BOC2低剂量组	5.39±0.59^ab	0.36±0.06^ab
BOC2高剂量组	3.80±0.46^abc	0.41±0.06^ab
F	520.973^＊＊	31.964^＊＊

组别	腹水量/mL	胰腺干湿质量比/（g/g）
假手术组	0	0.51±0.09
模型组	7.89±0.53^a	0.22±0.05^a
BOC2低剂量组	5.39±0.59^ab	0.36±0.06^ab
BOC2高剂量组	3.80±0.46^abc	0.41±0.06^ab
F	520.973^＊＊	31.964^＊＊

组别	病理评分/分	CD11b阳性细胞数/（个/视野）
假手术组	0	0
模型组	13.32±0.93^a	90.50±6.35^a
BOC2低剂量组	10.27±0.89^ab	47.60±2.95^ab
BOC2高剂量组	5.98±0.75^abc	22.40±2.72^abc
F	601.452^＊＊	1 068.648^＊＊

BOC2抑制N-甲酰肽/甲酰肽受体信号通路减轻SAP炎症损伤的机制研究

Mechanism study of BOC2 alleviating SAP inflammatory damage by inhibiting N-formyl peptide/formyl peptide receptor pathway

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 10

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

组别	MT-ND1	MT-ND2	MT-ND3
假手术组	0.06±0.01	0.13±0.01	0.08±0.01
模型组	0.72±0.02^a	0.64±0.02^a	0.38±0.02^a
BOC2低剂量组	0.34±0.02^ab	0.08±0.01^ab	0.22±0.04^ab
BOC2高剂量组	0.25±0.05^abc	0.09±0.01^ab	0.09±0.01^bc
F	297.968^＊＊	1 952.960^＊＊	100.922^＊＊
组别	MT-ND4	MT-ND5	MT-ND6
假手术组	0.90±0.08	0.27±0.06	0.08±0.01
模型组	0.97±0.09	0.87±0.07^a	0.81±0.08^a
BOC2低剂量组	0.95±0.08	0.46±0.03^ab	0.53±0.02^ab
BOC2高剂量组	0.91±0.08	0.40±0.03^ab	0.29±0.07^abc
F	0.461	85.969^＊＊	98.705^＊＊

组别	FPR1	FPR2
假手术组	64.71±5.37	1.84±0.77
模型组	158.04±8.15^a	90.19±6.47^a
BOC2低剂量组	121.24±10.53^ab	59.72±4.22^ab
BOC2高剂量组	57.85±3.08^abc	20.92±2.53^abc
F	423.016^＊＊	937.290^＊＊

组别	IL-1β	IL-6	TNF-α
假手术组	3.92±0.49	19.48±2.34	15.52±2.42
模型组	14.35±2.81^a	83.36±7.80^a	53.99±5.25^a
BOC2低剂量组	10.22±2.34^ab	62.95±10.10^ab	47.87±5.54^ab
BOC2高剂量组	8.33±1.51^abc	47.98±4.45^abc	35.38±4.06^abc
F	46.966^＊＊	153.786^＊＊	143.213^＊＊

组别	IL-1β	IL-6	TNF-α
假手术组	1.00±0.05	1.00±0.09	1.00±0.06
模型组	8.01±0.66^a	49.72±5.11^a	39.98±3.01^a
BOC2低剂量组	4.01±0.36^ab	18.11±1.80^ab	9.88±1.03^ab
BOC2高剂量组	2.11±0.25^abc	11.45±1.24^abc	4.67±0.77^abc
F	483.861^＊＊	456.466^＊＊	942.534^＊＊

[1]	姜天佑, 李敏, 孙碧文, 李越洋, 邢丽静, 田晨. Let-7b诱导白血病相关巨噬细胞复极抑制AML的发展[J]. 天津医药, 2026, 54(3): 225-231.
[2]	张婧, 魏玉英, 宁海虹, 韦红梅, 王嘉玮, 曹薇, 吴宾. DUSP9在2型糖尿病心肌病小鼠心肌损伤中的保护作用及其机制[J]. 天津医药, 2026, 54(3): 238-244.
[3]	黄熷远, 付靖, 赵亚, 王龙灏, 仓顺东. 非小细胞肺癌EGFR-TKI耐药与p53基因突变的研究进展[J]. 天津医药, 2026, 54(3): 333-336.
[4]	楚兴, 刘磊, 杨华, 陈宏. 胆总管结石并发急性胆源性胰腺炎的危险因素及预测模型的构建[J]. 天津医药, 2026, 54(1): 35-40.
[5]	万艳波, 刘明, 王勇. 秦皮甲素调节HMGB1/RAGE信号通路对缺氧/复氧诱导的心肌细胞损伤的影响[J]. 天津医药, 2025, 53(8): 796-801.
[6]	陈慧, 赵凯, 刘振国, 常瑛, 巨康璐. 金丝桃素通过调控NLRP3炎症小体改善小鼠急性胰腺炎的机制探讨[J]. 天津医药, 2025, 53(8): 820-825.
[7]	贾文歆, 周利娟, 王丽香. 血清CCL21、NLRP3与脑梗死患者机械取栓术后出血转化的相关性研究[J]. 天津医药, 2025, 53(7): 700-703.
[8]	吴素勤, 徐子舒, 许智晶, 吴洁, 王聪梅. 重症颅脑损伤减压术患者血清MMP-10、TLR2水平及其与疾病转归的关系[J]. 天津医药, 2025, 53(7): 704-708.
[9]	杜凌云, 王耀武, 任楠. 肾透明细胞癌中PRMT2、TRAF2与转移相关基因表达对预后的评估价值[J]. 天津医药, 2025, 53(5): 492-497.
[10]	董丹, 陈立娟, 俞荷花. 急性胰腺炎并发低血压的危险因素分析及预测模型建立[J]. 天津医药, 2025, 53(5): 509-513.
[11]	邓海娟, 权永娟, 李芳. 妊娠期糖尿病患者血清GPER1、CFH水平与妊娠结局的关系[J]. 天津医药, 2025, 53(4): 369-373.
[12]	郑少阳, 智慧, 王曼, 武冰, 张清格, 李冠阳. 酒精性肝病患者外周血sTim-3、sST2水平与疾病严重程度的相关性[J]. 天津医药, 2025, 53(4): 383-388.
[13]	彭溪, 杨莉莉, 刘敏, 张峻梅. 肺部肺炎克雷伯菌感染患者血清SOCS-1、sTREM-2、ACLY变化及临床意义[J]. 天津医药, 2025, 53(4): 397-401.
[14]	张叶杭, 牛向东, 耿一鸣. 血清sST2、DcR3联合动态心电图对无症状性心肌缺血的诊断价值[J]. 天津医药, 2025, 53(4): 420-424.
[15]	丁杨娟, 夏时海, 许威, 高庆红, 刘涛涛. 氧化应激及抗氧化剂在急性胰腺炎中的研究进展[J]. 天津医药, 2025, 53(4): 444-448.